Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.51 |
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936593 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9062184 | 1.00 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL3229583 | 0.89 | CTSK (0.49) | CTSKCTSS | |
| SCHEMBL3213512 | 0.89 | CTSK (0.49) | CTSKCTSS | |
| SCHEMBL28132863 | 0.88 | CTSK (0.48) | CTSKCTSS | |
| SCHEMBL28465534 | 0.88 | CTSK (0.48) | CTSKCTSS | |
| SCHEMBL4935587 | 0.88 | CTSK (0.48) | CTSKCTSS | |
| SCHEMBL6684772 | 0.88 | CA1 (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL13669545 | 0.88 | CTSK (0.54) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL29265449 | 0.87 | CA1 (0.42) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108025085-A | Antibody Drug Conjugates (ADCs) of KSP inhibitors and anti-B7H 3 antibodies | 拜耳制药股份公司 | 2018-05-11 | — | — | CN | disclosed |
| CN-108025086-A | Antibody-active agent conjugates (ADC) of KSP inhibitors and anti-B7H 3 antibodies | 拜耳制药股份公司 | 2018-05-11 | — | — | CN | disclosed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2200439-A1 | HDAC INHIBITORS | Lixte Biotechnology, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| US-20090156646-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| EP-1921066-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| CN-101090909-A | Antibacterial amide macrocycles IV | AICURIS GMBH & CO KG (DE) | 2007-12-19 | — | — | CN | disclosed |
| EP-0717040-A1 | Thiazine or thiazepine derivatives which inhibit NOS | Japan Tobacco Inc. (JP) | 1996-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | CTSK 1308/4885CTSS 3138/4885CA1 4251/4885 |
| US-20090156646-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | GNRHR, PGR, MC1R | CTSK 3415/4885CTSS 2424/4885CA1 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.